Farxiga EMA vs FDA Approach: How Two Regulators Evaluated Dapagliflozin Differently

When and Why the Two Agencies First Approved Dapagliflozin

The EMA beat the FDA to dapagliflozin by more than 14 months. The EMA's Committee for Medicinal Products for Human Use (CHMP) issued a positive opinion in November 2012, and the European Commission granted marketing authorization shortly afterward. The FDA did not approve Farxiga until January 8, 2014, after requesting an additional cardiovascular outcomes trial to rule out excess cardiac risk, a requirement that shaped the entire SGLT2 inhibitor regulatory timeline.

Why the FDA Delayed Its Decision

AstraZeneca first submitted a New Drug Application for dapagliflozin in 2011. The FDA's Endocrinologic and Metabolic Drugs Advisory Committee voted 9-6 against approval at an initial 2011 meeting, citing concerns about bladder cancer signals seen in early trial data and requesting a larger cardiovascular safety dataset [1]. The FDA specifically pointed to a numeric imbalance in bladder cancer cases (10 dapagliflozin vs. 1 placebo across pooled trials) and asked AstraZeneca to conduct a dedicated cardiovascular outcomes trial before full approval could be granted [2].

Why the EMA Moved First

The EMA's scientific assessment concluded that the bladder cancer signal did not meet the threshold for a causal relationship given the small absolute numbers and short latency period. The CHMP accepted the cardiovascular safety data available at the time as sufficient to support a positive benefit-risk balance for adults with type 2 diabetes whose blood glucose was inadequately controlled with diet alone or in combination with other antidiabetic agents [3]. This divergence illustrates that the two agencies apply different evidentiary thresholds even when reviewing identical trial packages.

What the FDA Label (Prescribing Information) Actually Says

The current FDA Prescribing Information for Farxiga covers three distinct indications, each with its own patient population, dose, and outcome language [4].

Indication 1: Type 2 Diabetes Mellitus

The label approves Farxiga 5 mg or 10 mg once daily to improve glycemic control in adults with type 2 diabetes as an adjunct to diet and exercise. The label explicitly states that Farxiga is not indicated for type 1 diabetes or for patients with an estimated glomerular filtration rate (eGFR) below 25 mL/min/1.73 m² when used for glycemic control.

Indication 2: Heart Failure with Reduced Ejection Fraction

The May 2020 expansion, driven by DAPA-HF results published in the New England Journal of Medicine in 2019, approves Farxiga 10 mg once daily to reduce the risk of cardiovascular death and worsening heart failure in adults with HFrEF (ejection fraction <40%) [5]. This was the first SGLT2 inhibitor FDA approval for a non-diabetic cardiovascular indication, a genuinely significant regulatory boundary crossed.

The DAPA-HF trial (N=4,744) showed that dapagliflozin 10 mg reduced the composite primary endpoint of worsening heart failure or cardiovascular death by 26% relative to placebo (hazard ratio 0.74; 95% CI 0.65 to 0.85; P<0.001). Benefit appeared consistent in patients with and without type 2 diabetes [5].

Indication 3: Chronic Kidney Disease

The April 2021 CKD expansion, supported by DAPA-CKD data published in the New England Journal of Medicine in 2020, approves Farxiga 10 mg once daily to reduce the risk of sustained eGFR decline, end-stage kidney disease, cardiovascular death, and hospitalization for heart failure in adults with CKD at risk of progression [6]. The label specifies a minimum eGFR of 25 mL/min/1.73 m² for this indication.

In DAPA-CKD (N=4,304), dapagliflozin reduced the primary composite endpoint by 39% relative to placebo (hazard ratio 0.61; 95% CI 0.51 to 0.72; P<0.001), prompting the data monitoring committee to stop the trial early [6].

What the EMA Label (Forxiga SmPC) Actually Says

The Summary of Product Characteristics (SmPC) for Forxiga in the European Union covers the same three broad therapeutic areas as the FDA label but with differences in exact population definitions, contraindication language, and the framing of benefit-risk statements [7].

Differences in Type 2 Diabetes Language

The EMA SmPC originally restricted Forxiga in patients with eGFR <60 mL/min/1.73 m² for the glucose-lowering indication, a more conservative cut-off than the FDA's initial label. Subsequent SmPC updates aligned more closely with CREDENCE and DAPA-CKD data and progressively relaxed the renal restriction [7].

Heart Failure: HFrEF and Then HFpEF

The EMA approved the HFrEF indication for Forxiga in August 2020, three months after the FDA. The EMA label specifies the same 10 mg once-daily dose and the same ejection fraction threshold (EF <40%). A key additional step: the EMA subsequently evaluated dapagliflozin for heart failure with preserved ejection fraction (HFpEF) based on EMPEROR-Preserved and DELIVER trial data. The FDA also granted a label update for HFpEF in 2023 after the DELIVER trial (N=6,263) showed a 18% relative risk reduction in the composite of cardiovascular death or worsening heart failure (hazard ratio 0.82; 95% CI 0.73 to 0.92; P<0.001) [8].

Contraindication Language

The EMA SmPC lists type 1 diabetes as a contraindication (a hard stop), while the FDA label lists it as a condition for which Farxiga is "not indicated" rather than formally contraindicated, a distinction with real prescribing implications in jurisdictions that treat contraindications as absolute prohibitions [4][7].

Post-Market Safety Requirements: FDA vs. EMA

Both agencies imposed post-market commitments on AstraZeneca, but the mechanisms and scope differ in meaningful ways.

FDA Post-Market Commitments

The FDA required AstraZeneca to conduct a cardiovascular outcomes trial (fulfilled by DECLARE-TIMI 58, N=17,160) as a condition of approval and to submit periodic safety reports through the FDA Sentinel System [9]. DECLARE-TIMI 58, published in the New England Journal of Medicine in 2019, showed dapagliflozin was non-inferior to placebo for the primary safety endpoint of major adverse cardiovascular events (MACE) (hazard ratio 0.93; 95% CI 0.84 to 1.03) and was superior on the composite of CV death or hospitalization for HF (hazard ratio 0.83; 95% CI 0.73 to 0.95) [9].

The FDA also issued a Drug Safety Communication in 2015 warning about diabetic ketoacidosis (DKA) risk across all SGLT2 inhibitors, a class-wide communication that required label updates for Farxiga and its competitors [10]. A 2018 FDA Safety Communication added Fournier's gangrene (necrotizing fasciitis of the perineum) as a labeled risk after 12 cases were identified in the FDA Adverse Event Reporting System (FAERS) between 2013 and 2018 [11].

EMA Pharmacovigilance Obligations

The EMA requires AstraZeneca to submit Periodic Safety Update Reports (PSURs) for Forxiga on a defined schedule. The Pharmacovigilance Risk Assessment Committee (PRAC) reviews each PSUR and issues recommendations that can trigger SmPC amendments. The EMA has used this mechanism to update Forxiga's risk minimization measures on DKA, urinary tract infections, and lower-limb amputation signals that emerged from post-approval real-world data [3][7].

The EMA's approach differs from the FDA's in that it relies more heavily on European real-world pharmacovigilance databases (EudraVigilance) rather than a centralized active surveillance system comparable to FDA Sentinel. Both approaches catch signals, but the data sources and adjudication timelines differ.

Bladder Cancer: The Original Divergence Point Revisited

The bladder cancer signal that nearly stopped the FDA approval in 2011 has been evaluated repeatedly in post-market studies. A 2016 analysis of pooled AstraZeneca clinical trial data (N=6,045 dapagliflozin, N=3,512 comparator) found no statistically significant increase in bladder cancer incidence [12]. A 2022 population-based cohort study published in BMJ using data from the Clinical Practice Research Datalink (CPRD) confirmed no excess bladder cancer risk with SGLT2 inhibitors as a class [13].

The FDA updated the Farxiga label to remove the bladder cancer warning in 2022 after reviewing this accumulated evidence. The EMA, which never formally listed bladder cancer as a contraindication or black-box warning, treated the resolution similarly [7].

This sequence illustrates one of the sharpest regulatory contrasts between the two agencies. The FDA held back approval for 14 months over a signal the EMA assessed as insufficient to block authorization. Post-market data ultimately supported the EMA's original assessment.

Labeling Language Comparison: Side by Side

The table below maps the primary label differences between the FDA Prescribing Information (current as of 2024) and the EMA SmPC (current as of 2023). These distinctions matter to clinicians practicing across jurisdictions or reviewing international trial data.

| Domain | FDA Farxiga Label | EMA Forxiga SmPC | |---|---|---| | Type 1 diabetes | Not indicated | Contraindicated | | Min eGFR for T2D glycemic use | 25 mL/min/1.73 m² | 45 mL/min/1.73 m² (historical; see SmPC) | | HFrEF indication date | May 2020 | August 2020 | | HFpEF indication | Yes (2023) | Yes (2023) | | DKA warning level | Warnings and Precautions | Warnings and Precautions | | Bladder cancer warning | Removed 2022 | Never formally added | | Fournier's gangrene | Warnings and Precautions | Warnings and Precautions | | Lower-limb amputation | Not a labeled class warning | Was labeled; reviewed and retained for pioglitazone combination |

Dapagliflozin Safety Profile: What Both Labels Agree On

Despite the differences above, the FDA and EMA agree on the core safety signals for dapagliflozin.

Diabetic Ketoacidosis

Both agencies require a DKA warning. DKA with SGLT2 inhibitors can occur at relatively normal blood glucose levels (euglycemic DKA), making it harder to recognize. The FDA's 2015 Safety Communication noted cases requiring hospitalization across the SGLT2 inhibitor class [10]. Clinicians should advise patients to hold dapagliflozin at least 3 days before elective surgery, consistent with the American Diabetes Association's 2024 Standards of Medical Care in Diabetes [14].

Genital Mycotic Infections

Both labels report genital mycotic infections in approximately 6 to 8% of women and 2 to 4% of men in clinical trials, consistent with the glucosuria mechanism that promotes Candida overgrowth [4][7].

Volume Depletion

Both labels warn about volume depletion, particularly in patients aged 65 and older, those on loop diuretics, and those with baseline eGFR <60 mL/min/1.73 m². The FDA label recommends assessing volume status before initiating therapy in these groups [4].

Urinary Tract Infections

Both agencies note a modestly elevated rate of urinary tract infections with dapagliflozin. Serious urinary tract infections, including urosepsis and pyelonephritis, have been reported and are listed in both labels' Warnings and Precautions sections.

How Clinicians and Patients Should Read These Differences

Regulatory label differences between FDA and EMA are not academic. Physicians practicing in the United States follow the FDA Prescribing Information as the controlling document. Physicians in EU member states follow the SmPC.

For a US prescriber, the practical takeaways are:

• Farxiga is approved for three indications: T2D glycemic control, HFrEF (now including HFpEF), and CKD with eGFR ≥25 mL/min/1.73 m².
• The bladder cancer warning was removed in 2022; the DKA and Fournier's gangrene warnings remain active.
• The DAPA-HF trial showed a number needed to treat (NNT) of 21 over 18 months to prevent one primary endpoint event in patients with HFrEF [5], a clinically meaningful effect size that justifies use even in patients without diabetes.

The 2022 ACC/AHA Heart Failure Guidelines state: "In patients with HFrEF, SGLT2 inhibitors are recommended to reduce the risk of HF hospitalization and cardiovascular death (Class I, Level of Evidence A)" [15]. Dapagliflozin is one of two agents (the other being empagliflozin) supporting that Class I recommendation.

FDA Sentinel vs. EudraVigilance: The Surveillance Architecture Behind the Labels

Post-approval safety surveillance shapes labeling updates, so the tools each agency uses matter.

FDA Sentinel System

The FDA Sentinel System is an active surveillance network drawing on claims and electronic health record data from more than 300 million patient-years of longitudinal data [16]. Sentinel allows the FDA to run near-real-time queries on specific drug-event pairs. For dapagliflozin, Sentinel data contributed to the bladder cancer reassessment and to ongoing monitoring of DKA rates in real-world use.

EudraVigilance

EudraVigilance is the EMA's centralized pharmacovigilance database for adverse drug reaction reports from EU member states. It is primarily a spontaneous reporting system rather than an active surveillance network, meaning it captures reported events rather than actively interrogating population-level records. The PRAC uses EudraVigilance alongside published epidemiological studies to make benefit-risk recommendations that feed into SmPC updates.

The architectural difference matters: active surveillance (FDA Sentinel) can detect signals earlier in lower-incidence populations; spontaneous reporting (EudraVigilance) captures a broader geographic spread of real-world experience but with inherent underreporting.